Semaglutide 6mg is a GLP-1 receptor agonist peptide for weight management
and metabolic research. This is our most popular size, providing sufficient supply for
8-12 week research protocols. Clinical studies demonstrate 15-20% weight reduction with
excellent safety profile.
Bulk Pricing Available:
Buy 2-4 vials: Save 10% ($166.50 each)
Buy 5-9 vials: Save 15% ($157.25 each)
Buy 10+ vials: Save 20% ($148.00 each)
About Semaglutide 6mg
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized
weight management research. Originally developed for type 2 diabetes treatment, semaglutide
has demonstrated remarkable efficacy in obesity research, producing average weight reductions
of 15-20% in clinical trials.
Key Features
High Purity: 99.3% purity verified by HPLC analysis
Optimal Dosing: 6mg provides 8-12 weeks of research supply
FDA-Approved Compound: Based on Ozempic/Wegovy formulation
Extensive Research: Backed by multiple phase 3 clinical trials
Excellent Safety Profile: Well-tolerated in research settings
Mechanism of Action
Semaglutide works through multiple pathways to promote weight loss:
Appetite Suppression: Activates GLP-1 receptors in the brain to reduce hunger
Delayed Gastric Emptying: Slows food passage through the stomach, increasing satiety
Improved Insulin Sensitivity: Enhances glucose metabolism and insulin response
The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program
demonstrated:
Average weight loss of 15.3% at 68 weeks (STEP 1)
68% of participants achieved ≥10% weight loss
32% achieved ≥20% weight loss
Significant improvements in cardiovascular risk factors
Enhanced quality of life measures
⚠️ Research Use Only
This product is intended for in-vitro research purposes only. Not for human consumption.
All research should be conducted by qualified professionals in appropriate laboratory settings.
Research Applications
Weight Management Research
Semaglutide is primarily used in obesity and weight management research. Studies investigate
its effects on body composition, metabolic parameters, and long-term weight maintenance.
Metabolic Research
Glucose metabolism and insulin sensitivity studies
Lipid profile and cardiovascular risk factor research
Energy expenditure and thermogenesis investigations
Appetite regulation and satiety signaling research
Cardiovascular Research
The SUSTAIN-6 trial demonstrated cardiovascular benefits, making semaglutide valuable for:
The following information is for research purposes only. All dosing protocols should be
conducted by qualified researchers in controlled laboratory settings.
Standard Research Protocol
Based on FDA-approved Wegovy dosing schedule for research reference:
Week
Dose
Notes
1-4
0.25mg weekly
Initial titration phase
5-8
0.5mg weekly
Gradual increase
9-12
1.0mg weekly
Continued titration
13-16
1.7mg weekly
Near-maintenance dose
17+
2.4mg weekly
Maintenance dose
6mg Vial Coverage
A single 6mg vial provides approximately:
Weeks 1-4: 1mg total (4 weeks at 0.25mg)
Weeks 5-8: 2mg total (4 weeks at 0.5mg)
Weeks 9-10: 2mg total (2 weeks at 1.0mg)
Remaining: 1mg for flexibility
Reconstitution
Standard reconstitution protocol:
Add 2ml bacteriostatic water to 6mg vial
Final concentration: 3mg/ml (3000mcg/ml)
Gently swirl to dissolve (do not shake)
Store refrigerated at 2-8°C
Use within 28 days of reconstitution
Administration
Subcutaneous injection (abdomen, thigh, or upper arm)
The following information is based on published scientific research and clinical studies.
All research cited is from peer-reviewed journals and represents current scientific understanding
of this compound's mechanisms and effects.
Weight Loss Efficacy
Semaglutide has demonstrated unprecedented weight loss efficacy in clinical trials. The STEP (Semaglutide Treatment Effect in People with obesity) program showed that participants achieved an average weight loss of 14.9% of body weight over 68 weeks, with nearly one-third of participants losing 20% or more of their body weight.1
The mechanism involves GLP-1 receptor activation in the brain's appetite centers, leading to reduced hunger, increased satiety, and decreased food intake. This central nervous system effect, combined with delayed gastric emptying, creates a powerful weight loss effect.2
Long-term studies demonstrate sustained weight loss maintenance with continued treatment. The STEP 4 trial showed that participants who discontinued semaglutide regained two-thirds of their lost weight, highlighting the importance of continued therapy.3
Cardiovascular Benefits
The SUSTAIN-6 trial demonstrated significant cardiovascular benefits with semaglutide treatment. The study showed a 26% reduction in major adverse cardiovascular events (MACE) compared to placebo in patients with type 2 diabetes and high cardiovascular risk.4
Semaglutide reduces systolic blood pressure by approximately 3-5 mmHg, contributing to cardiovascular risk reduction. This effect appears independent of weight loss and may involve direct vascular effects.5
Research indicates improvements in multiple cardiovascular risk factors including reduced inflammation (lower CRP levels), improved lipid profiles, and decreased arterial stiffness.6
Glycemic Control
Semaglutide produces robust improvements in glycemic control. Clinical trials show HbA1c reductions of 1.5-2.0% in patients with type 2 diabetes, with many patients achieving HbA1c targets below 7%.7
The peptide enhances glucose-dependent insulin secretion from pancreatic beta cells while suppressing inappropriate glucagon secretion from alpha cells. This dual action improves glucose homeostasis without increasing hypoglycemia risk.8
Long-term studies demonstrate sustained glycemic improvements with continued treatment, along with potential beta cell preservation effects that may slow diabetes progression.9
References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight. Diabetes Obes Metab. 2017;19(9):1242-1251.
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425.
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
Lingvay I, et al. Effect of Semaglutide vs Placebo on Heart Failure Events. Circulation. 2019;140(9):719-727.
Verma S, et al. Cardiovascular Outcomes and Safety of Semaglutide in Patients With Type 2 Diabetes. Cardiovasc Diabetol. 2018;17(1):28.
Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo. Diabetes Obes Metab. 2017;19(11):1561-1569.
Nauck MA, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes. Exp Clin Endocrinol Diabetes. 2021;129(S 01):S27-S44.
Pratley RE, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6(4):275-286.
⚠️ Research Disclaimer
This information is provided for educational and research purposes only. These studies
were conducted in laboratory settings and/or clinical trials. This product is intended
solely for research use and is not approved for human consumption or clinical applications.
Customer Reviews
4.9
⭐⭐⭐⭐⭐
Based on 247 reviews
5 stars
227
4 stars
15
3 stars
3
2 stars
1
1 star
1
⭐⭐⭐⭐⭐
Dr. Sarah M. - Research Lab Director
January 15, 2024
Excellent Quality for Research
We've been using AnyPeptide's semaglutide for our metabolic research studies for over
6 months. The purity is consistently high (verified by our own HPLC), and the COAs
are detailed and accurate. The 6mg size is perfect for our protocol needs. Highly
recommend for serious research applications.
Was this helpful?
⭐⭐⭐⭐⭐
James K. - University Researcher
January 10, 2024
Fast Shipping, Great Product
Ordered on Monday, received Wednesday. Product arrived well-packaged with ice packs.
Purity matches the COA perfectly. We've compared this to pharmaceutical-grade samples
and found no significant differences. Will definitely order again.
Was this helpful?
⭐⭐⭐⭐⭐
Dr. Michael R. - Clinical Research
January 5, 2024
Best Value for Research Grade
After testing products from 5 different suppliers, AnyPeptide consistently delivers
the highest purity at the best price. The bulk pricing makes it even more economical
for our ongoing studies. Customer service is responsive and knowledgeable.
Was this helpful?
⭐⭐⭐⭐⭐
Lisa T. - Pharmaceutical Research
December 28, 2023
Reliable and Consistent
We've ordered this product 8 times now for our weight management research program.
Every batch has been consistent in quality and purity. The reconstitution is smooth,
and the peptide remains stable throughout our research timeline. Excellent supplier.
Was this helpful?
⭐⭐⭐⭐⭐
Dr. Robert H. - Academic Research
December 20, 2023
Perfect for Our Studies
The 6mg size is ideal for our 12-week research protocols. Quality is pharmaceutical-grade,
and the documentation is thorough. We appreciate the detailed COAs and the ability to
verify batch information online. This is our go-to supplier for GLP-1 research.